Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial
Journal of Clinical Oncology · 10.08.2026 · 44 (23) · 2187-2197
DOI: 10.1200/jco-26-00788 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.08.2026. Verfasst von Tanios S Bekaii-Saab und 26 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Phoenix, AZ. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Receptor, Fibroblast Growth Factor, Type 2, Bile Duct Neoplasms, Pyrimidines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Cholangiocarcinoma is a rare cancer associated with poor prognosis. Pemigatinib was the first FGFR1-3 inhibitor approved for second-line therapy and beyond, on the basis of the phase II FIGHT-202 trial. Here, we assess efficacy and safety of first-line pemigatinib. METHODS FIGHT-302 is a phase III, randomized, global trial evaluating pemigatinib as first-line therapy (ClinicalTrials.gov identifier: NCT03656536 ). Adults with advanced cholangiocarcinoma with FGFR2 rearrangement were randomized 1:1 to receive pemigatinib (13.5 mg once daily) or chemotherapy (1,000 mg/m 2 gemcitabine plus 25 mg/m 2 cisplatin once per day on days 1 and 8 of every 3-week cycle for ≤8 cycles) and were stratified by prior receipt of chemotherapy, geographic region, and tumor burden. Pemigatinib crossover was allowed for patients progressing on chemotherapy. The primary end point was progression-free survival (PFS). Secondary efficacy, safety, and exploratory end points were also analyzed. RESULTS Overall, 4,563 patients were prescreened, 196 were screened, and 167 randomly assigned to receive pemigatinib (n = 83) or chemotherapy (n = 84) before early closure of the study because of a change in standard of care. The median PFS was 8.3 months in the pemigatinib group versus 6.8 months in the chemotherapy group (hazard ratio, 0.58 [95% CI, 0.39 to 0.87]; nominal P = .0078); objective response rate was 47% versus 15%, and the median duration of response was 14.2 versus 6.3 months. Median overall survival was similar (24.4 v 25.0 months, respectively). In the crossover group (n = 42, second-line pemigatinib), the median PFS was 8.1 months. Safety was consistent with the known profile of pemigatinib. CONCLUSION To our knowledge, this was the largest, first-line, randomized, phase III trial of a targeted therapy for advanced FGFR2- rearranged cholangiocarcinoma. Pemigatinib demonstrated prolonged median PFS compared with chemotherapy, with no new safety findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mayo Clinic, Phoenix, AZ.
- University of Verona, Verona, Italy.
- Amsterdam UMC, Amsterdam, the Netherlands.
- Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy.
- Mayo Clinic, Rochester, MN.
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
ORCID-Profile: Tanios S Bekaii-Saab, Davide Melisi, Nguyen Tran, Giampaolo Tortora, Filippo De Braud, Sara Lonardi, Hani Babiker, Lorenzo Fornaro, Andrés Muñoz Martín, John Bridgewater, Jennifer J Knox, Judith De Vos-Geelen, Martin Scott-Brown, Junji Furuse, Lorenza Rimassa, Arndt Vogel
Zitieren
APA
Bekaii-Saab, T. S., Melisi, D., Wilmink, H., Garufi, C., Tran, N., Tortora, G., De Braud, F., Frodin, J. E., Lonardi, S., Lin, E., Babiker, H., Lin, B., Fornaro, L., Muñoz Martín, A., Bridgewater, J., Knox, J. J., De Vos-Geelen, J., Scott-Brown, M., Veronese, L., …, & Vogel, A. (2026). Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial. Journal of Clinical Oncology, 44(23), 2187-2197. https://doi.org/10.1200/jco-26-00788
Vancouver
Bekaii-Saab TS, Melisi D, Wilmink H, Garufi C, Tran N, Tortora G, et al. Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial. Journal of Clinical Oncology. 2026;44(23):2187-2197. doi:10.1200/jco-26-00788
BibTeX
@article{BekaiiSaab2026,
author = {Bekaii-Saab, Tanios S and Melisi, Davide and Wilmink, Hanneke and Garufi, Carlo and Tran, Nguyen and Tortora, Giampaolo and De Braud, Filippo and Frodin, Jan-Erik and Lonardi, Sara and Lin, Emily and Babiker, Hani and Lin, Bruce and Fornaro, Lorenzo and Muñoz Martín, Andrés and Bridgewater, John and Knox, Jennifer J and De Vos-Geelen, Judith and Scott-Brown, Martin and Veronese, Luisa and Ioannidis, Sonia and Gilmartin, Aidan and Janik, John E and Guo, Yufei and Furuse, Junji and Ioka, Tatsuya and Rimassa, Lorenza and Vogel, Arndt},
title = {Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {23},
pages = {2187--2197},
doi = {10.1200/jco-26-00788}
}
EUVIMED